Klean Research

THE STANDARD / NOV 16 2026

GHK-Cu Regulatory Status in 2026

A reading of public FDA records as of 16 November 2026. No GHK-Cu drug approval turned up in a Drugs@FDA search. The cosmetic rule, the compounding categories, and the words research use only are separate things.

Abstract header for a note on GHK-Cu regulatory status: a stack of blank paper and an unreadable seal in cool gray light
KLEAN RESEARCH / KLN-0007

This page describes public documents. It does not say what anyone should do with a material, and it does not predict what FDA will decide later. The documents below were read on 16 November 2026. FDA revises lists. A later page from the agency supersedes this summary.

The chemistry of the copper(II) complex is a different subject, covered in Why Is GHK-Cu Blue?. The GHK-Cu catalogue entry is the research material this site lists. It is not an FDA approval.

No drug approval located

Drugs@FDA, queried through the openFDA drug endpoint on 16 November 2026, returned no matches for an active ingredient named prezatide, prezatide copper, or GHK.

A query on the substance-name field for the string GHK-Cu returned one application: NDA 213227, Detectnet, sponsored by Curium. The ingredient on that application is copper Cu-64 dotatate. That is a different copper-containing drug. It is not the tripeptide complex.

FDA's Global Substance Registration System has records titled prezatide and prezatide copper acetate. Each record states that UNII availability does not imply any regulatory review or approval. A substance identifier is not an approval.

Skin and hair products are not a drug approval

FDA's page on its authority over cosmetics says the law does not require cosmetic products and ingredients, other than color additives, to have FDA approval before they go on the market. The same page says cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives. That is a statement about cosmetics as a class. It is not a finding about any named product, and it is not a drug approval.

Pickart and Margolina, in a 2018 review, state that GHK-Cu is widely used in skin and hair products. That sentence is the review's description of use. This article does not carry over the rest of that paper.

This catalogue says something narrower about its own materials. The sitewide notice reads: "For laboratory research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. These products have not been evaluated by the FDA or Health Canada." That notice is the seller's classification of what it ships. It is not FDA's classification of every product, elsewhere, that contains the tripeptide.

Compounding lists, and what category 1 is

Section 503A of the Federal Food, Drug, and Cosmetic Act is the compounding provision FDA describes on its bulk-substances page. That page says state-licensed physicians and pharmacists compounding under section 503A may only use bulk drug substances that comply with an applicable USP or NF monograph, or are components of FDA-approved drug products if no such monograph exists, or appear on FDA's 503A bulks list if there is no monograph and the substance is not a component of an FDA-approved drug.

While that list is still being built, FDA published an interim policy with three categories for nominated substances:

  • Category 1: substances that may be eligible for the 503A bulks list, were nominated with enough supporting information for FDA to evaluate them, and do not appear on any other list. FDA says it does not intend to take action against a compounder for compounding with a category 1 substance when the conditions in the guidance are met.
  • Category 2: substances nominated with enough information to evaluate, but for which FDA has identified significant safety risks. FDA says it does not intend to adopt the category 1 policy for these.
  • Category 3: substances that may be eligible but were nominated without enough information to evaluate. They are not eligible for the category 1 policy.

FDA's page also says the agency does not intend to place substances nominated on or after 7 January 2025 into these categories, and that a category 1 substance can stay inside the interim policy until FDA decides on inclusion, or until FDA removes it.

Category 1 is an enforcement description for compounders who meet the guidance. It is not inclusion on the bulks list, and it is not an approval.

Where GHK-Cu sits on those lists

FDA's 503A category document, the file dated as updated 14 May 2026, has two statements that have to be read together.

The category 1 list, headed "Bulk Drug Substances Under Evaluation," includes the entry "GHK-Cu (except for injectable routes of administration)." The words in parentheses are the entry's name on that list. They are a boundary on the nomination. They are not instructions.

Above the list, the same file says that entry was removed from category 1 on 22 April 2026 because the nominators withdrew the nominations. On 5 May 2026, one nominator clarified that it had meant to withdraw only the nomination for the injectable route, and that it wanted to keep the nomination for other routes. The file says the entry will be added back to category 1. The 14 May 2026 list is the document that shows it there.

The same note says FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 "regarding the potential inclusion of GHK-Cu on the 503A bulks list." Potential inclusion is the document's phrase for a decision that has not been made.

A separate FDA page, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," puts "GHK-Cu (for injectable routes of administration)" in a table of nominations that were withdrawn. The page introduces that table as substances previously in category 2 whose nominations the nominators withdrew. GHK-Cu does not appear in the table of substances the same page lists as currently in category 2. FDA's note on the withdrawn row says: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." That is FDA's text for that row. This article does not add a conclusion of its own.

FDA's 503B nominated-substances file, retrieved from FDA's site on 16 November 2026, does not contain the string GHK.

The advisory committee has not met on this

FDA's page for the Pharmacy Compounding Advisory Committee says the agency will host a meeting before the end of February 2027. The agenda lists five bulk substances being considered for inclusion on the 503A bulks list: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor. The page says the time and location will be scheduled in the coming months, and that a Federal Register notice and a public docket are intended and are not yet the meeting.

The same page says advisory committees make non-binding recommendations. A recommendation, when one exists, is advice to the agency. It is not itself a listing, and it is not an approval. As of the page read on 16 November 2026, the meeting had not been given a day.

What "research use only" means

FDA uses the phrase for a defined class of products, and this site uses it as a limit on its own materials. They are not the same sentence.

FDA's guidance "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only," issued 25 November 2013, says an RUO product is an in vitro diagnostic product in the laboratory research phase of development, shipped or delivered for an investigation that is not subject to 21 CFR part 812. The guidance quotes 21 CFR 809.10(c)(2)(i): for a product in that phase, and not represented as an effective in vitro diagnostic product, the labeling bears "For Research Use Only. Not for use in diagnostic procedures." The guidance also says an IVD product should not be labeled this way if it is intended for clinical diagnostic use outside an investigation, and that FDA would consider such a product misbranded.

That rule is about diagnostic devices. A peptide is not made into an approved drug by printing the words, and the guidance does not define research chemicals. The label is not an approval of anything.

On this site the journal line printed at the end of every article is the wording for these pages: educational, and supplied strictly for in-vitro laboratory research. The catalogue notice quoted above is the matching line for the materials themselves.

What this page does not decide

No application named GHK, prezatide, or prezatide copper turned up in the Drugs@FDA search above. Category 1 on a May 2026 list is not the 503A bulks list. A committee meeting announced for before the end of February 2027 had not, on the page read here, been held. A review's statement that the complex is used in skin and hair products is not a drug approval. Cosmetic ingredients other than color additives are not pre-approved, and that general rule is not a certificate for a named jar.

The vendor checklist is the separate question of how a research supplier documents a lot. Regulatory status and a certificate answer different questions.

Frequently asked questions

Is there an FDA-approved GHK-Cu drug?

A Drugs@FDA search through openFDA on 16 November 2026 returned no application whose active ingredient name was GHK, prezatide, or prezatide copper. A substance-name query for GHK-Cu returned Detectnet, copper Cu-64 dotatate, which is a different drug. A UNII record says that a UNII does not imply regulatory review or approval.

Does use in skin and hair products make GHK-Cu an approved drug?

No. FDA's cosmetics page says cosmetic products and ingredients, other than color additives, do not need FDA premarket approval. A 2018 review states that GHK-Cu is widely used in skin and hair products. Neither statement is a drug approval.

What is the FDA compounding category for GHK-Cu?

FDA's 503A list updated 14 May 2026 places the entry GHK-Cu, except for one named route, in category 1, substances under evaluation. Category 1 is not inclusion on the 503A bulks list. FDA says it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about possible inclusion.

Has the advisory committee already decided?

No. FDA's meeting page says the committee will discuss GHK-Cu, that the time and location will be scheduled later, and that advisory committee recommendations are non-binding.

What does research use only mean?

In FDA's 2013 guidance, the phrase is a label for in vitro diagnostic products in the laboratory research phase. The guidance quotes a required statement from 21 CFR 809.10(c)(2)(i). That rule is about diagnostic devices. It is not a drug approval. On this site, the journal disclaimer is the wording used for these articles.

Questions on a specific compound? The research desk answers with documentation. Contact the research desk or browse the research library.

Sources

  1. openFDA Drugs@FDA endpoint, queried 16 November 2026. Active-ingredient searches for prezatide, "prezatide copper", and GHK returned no matches. A substance-name search for GHK-Cu returned NDA 213227, Detectnet (copper Cu-64 dotatate). https://api.fda.gov/drug/drugsfda.json
  2. FDA Global Substance Registration System. UNII A3LEI4P1NB, prezatide copper acetate, and UNII 39TG2H631E, prezatide. Both records state that UNII availability does not imply regulatory review or approval. https://precision.fda.gov/uniisearch/srs/unii/A3LEI4P1NB and https://precision.fda.gov/uniisearch/srs/unii/39TG2H631E
  3. FDA. "FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated." https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
  4. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. PMID 29986520. PMC6073405. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  5. FDA. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  6. FDA. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act" (category 1 list updated 14 May 2026). https://www.fda.gov/media/94155/download
  7. FDA. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. FDA. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act," retrieved 16 November 2026. https://www.fda.gov/media/94164/download
  9. FDA. "Meeting of the Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  10. FDA. "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff." Issued 25 November 2013. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only

KLEAN. — RESEARCH DESK

Questions on a specific compound? The research desk answers with documentation.

CONTINUE READING

GHK-Cu vs AHK-Cu, and What's in GLOW vs KLOW

READ ENTRY →

Why Is GHK-Cu Blue? What the Color Does and Doesn't Tell You

READ ENTRY →